Anthropic opened its virtual "Briefing: Enterprise Agents" event on Tuesday with a provocation. Kate Jensen, the company's head of Americas, told viewers that the hype around enterprise AI agents in ...

Microsoft has confirmed in its Windows IT Pro Blog the end-of-support timeline for three long-servicing Windows 10 releases from 2016 and outlined Extended Security Updates (ESUs) for organizations ...

For software developers today, staying competitive means embracing AI technologies. Here’s how some developers are staying ahead of the curve.

Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance and streaming services. He is passionate about language and technology, and has been an avid writer/reader of ...

U.S. Transportation Secretary Sean P. Duffy has unveiled the Administration’s new proposal to expand a Buy America public interest waiver for electric vehicle (EV) chargers that raises the required ...

It’s not goodbye, it’s see you again, friend. Mike Latullippe departs, we welcome a new show and an update on This Island Earth. After two incredible years of bringing energy, soul, and deep Detroit ...

SolarWinds, a provider of secure observability and IT management software, has updated its partner program with new benefits, enablement and demand generation investments designed to help partners ...

Under recent federal rulemaking, Part 2 Programs and HIPAA covered entities that process Part 2 Substance Use Disorder (SUD) records must update their Notice of ...

Chinese state-sponsored threat actors were likely behind the hijacking of Notepad++ update traffic last year that lasted for almost half a year, the developer states in an official announcement today.

Norwegian Cruise Line has updated its NCL Air policy, effective immediately, requiring all airfare bookings through the NCL Air program to schedule guests to arrive at least one day ahead of their ...

PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced that it will ...

Oral presentation to highlight first-ever clinical evidence supporting use of a targeted GYS1 substrate reduction therapy, ABX1100, in patients with late-onset Pompe disease (LOPD) In an oral ...